This is the first time to the authors’ knowledge that the fast (screening) protocol on the S-MAIA has been used in patients with CRB1-associated retinopathies, which allows rapid assessment of sensitivity and is easily integrated into a clinical trial setting. The gene discussed is CRB1; the disease is retinal disorder.